Det er kendt, at behandling med angiotensin- II receptorantagonister i 2. og 3. trimester af graviditeten inducerer human føtotoksicitet (nedsat nyrefunktion, oligohydramnios, føtal kraniel hypoplasi) og neonatal toksicitet (nyresvigt, hypotention, hyperkaliæmi) (se også pkt.
AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).